Where Are We Today with Infection Among Healthy Children in Saudi Arabia?
Overview
Affiliations
Background/aims: The available studies on Helicobacter pylori (H. pylori) prevalence among healthy asymptomatic population across Saudi Arabia suffers from significant limitations. We conducted this large population-based study to estimate the H. pylori seropositivity rate among apparently healthy children in Saudi Arabia, using anti-H. pylori immunoglobulin A (IgA) and IgG serology tests, and to study the influence of H. pylori infection on growth.
Materials And Methods: We conducted a cross-sectional study to screen apparently healthy school aged Saudi children (aged 6-15 years), attending primary and intermediate schools in Riyadh between 2014 and 2016, for H. pylori seropositivity by checking for the presence of anti-H. pylori IgG and IgA antibodies in serum specimens.
Results: Out of 3551 serum specimens, 1413 cases tested seropositive for H. pylori organism (40%): 430 (12.2%) were both IgG and IgA positive, 212 (6%) and 771 (21.7%) cases showed isolated positivity for IgG or IgA, respectively. Male gender, older age, lower levels of socioeconomic status (SES), and family members >10 were significantly associated with H. pylori seropositivity. The proportion of participants with short stature was significantly more in the H. pylori seropositive group than the seronegative group (OR1.249, confidence interval [1.020-1.531], P= 0.033). There was no significant association between H. pylori seropositivity and gastrointestinal symptoms.
Conclusion: The prevalence of H. pylori seropositivity among apparently healthy Saudi children (40%) is intermediate compared with that in developed and developing countries. The Saudi pediatric population shows a predominant IgA-type immunological response to H. pylori infection.
AlLehibi A, Alsubaie F, Alzahrani R, Ekhuraidah H, Koshan M, Alotaibi N Cureus. 2024; 16(5):e59912.
PMID: 38721481 PMC: 11078533. DOI: 10.7759/cureus.59912.
Abdelrahman H, Alotaibi S, Abanmi S, Alosaylan H, Almutairi A, Almutairi N J Pharm Bioallied Sci. 2024; 16(Suppl 1):S473-S476.
PMID: 38595531 PMC: 11001116. DOI: 10.4103/jpbs.jpbs_755_23.
Epidemiology, pathogenicity, risk factors, and management of infection in Saudi Arabia.
Ibrahim M Biomol Biomed. 2023; 24(3):440-453.
PMID: 37787623 PMC: 11088898. DOI: 10.17305/bb.2023.9575.
Hafiz T, DSa J, Zamzam S, Visbal Dionaldo M, Aldawood E, Madkhali N J Multidiscip Healthc. 2023; 16:1979-1988.
PMID: 37484821 PMC: 10361274. DOI: 10.2147/JMDH.S419630.
Molecular characterization of clinical isolates from Eastern Saudi Arabia.
Alkharsah K, Aljindan R, Alamri A, Alomar A, Al-Quorain A Saudi Med J. 2022; 43(10):1128-1135.
PMID: 36261204 PMC: 9994491. DOI: 10.15537/smj.2022.43.10.20220355.